We worked with one of Johnson and Johnson Vision’s key customers to improve the efficiency of cataract services, enabling more patients to be treated within the existing service. Using simulation we identified efficiencies that enabled more patients to be treated with the existing resources. Redesigning the pathway led to an additional 35 patients being treated each week, in excess of 1,680 per year.
We conducted a longitudinal analysis of patients and developed a pathway analysis to support change and improve resource use in the NHS severe asthma pathway.
The longitudinal analysis provided, for the ﬁrst time in this pathway, real world evidence using data at a patient level. It showed the impact that biologic treatment had on the number of avoided events and their associated costs for health economies in England.
We created a model to support change and improve resource use in the current analgesic pathway deployed in NHS Trusts’ Emergency Departments (EDs). The model aimed to improve care by enhancing patient throughput time, enabling faster and more effective analgesia thus reducing the need for sedation, and the concomitant risks and delays to patients.
We identified patients with severe liver disease who may be suited to a progressive treatment for which a recent study showed prolonged overall survival and possible disease modifying treatment in patients with decompensated cirrhosis. The analysis demonstrated the resources used by these patients and segmented those who would be better suited to the treatment. The analysis was used to engage senior NHS decision makers and support them to redesign patient pathways to improve patient outcomes.
Working jointly with 3 General Practices and our pharmaceutical client, we explored the link between opioids and the use of laxatives. The project aimed to reduce the population of patients on opioids, a key NHS target, whilst improving the management of adverse events for those that remained on them, primarily opioid induced constipation.
We mapped the breast cancer pathway, in particular considering the differences between the subcutaneous pathway and the infusion pathway. The analysis provided a clear understanding of the pathway and identified options for adding value with with our client's biosimilar product administered via infusion therapy.
We analysed the patient pathway for febrile neutropenia to establish how treatment varied across the country to identify areas for improvement and ways to enhance our client's value proposition. Our analysis identified how patients were referred, diagnosed, assessed, treated and discharged. Using secondary care data, we provided evidence to enhance our client's existing business case to present a more compelling case for change to improve patient outcomes.
We conducted a detailed analysis of the total knee replacement pathway to identify the most effective point for the introduction of a new device. Using data on the pathway, we developed a health economic model that could easily be adapted to show the impact on waiting
times, avoided total knee replacement surgeries and
achieved consequent savings through the use of
our client’s device at different stages in the patient
We were appointed to help our client get a better understanding of the rheumatoid arthritis patient pathway and identify opportunities to add value to the pathway through the introduction of their device and its potential associated services. Our analysis identified options to enable the client to engage the NHS in discussions on new ways to support patients with rheumatoid arthritis and therefore move the conversation away from purely one of price to one of overall value.
We conducted a detailed analysis of the pathway for patients with Parkinson's disease, including an analysis of secondary care data. We developed a simulation so our client could easily show the impact on NHS resources, such as funding, volumes of activity and healthcare utilisation when a dopamine agonist patch was introduced into the pathway.